NASDAQ: RLYB
Rallybio Corp Stock

$0.31-0.02 (-6.06%)
Updated Jun 20, 2025
RLYB Price
$0.31
Fair Value Price
$0.60
Market Cap
$12.73M
52 Week Low
$0.22
52 Week High
$1.60
P/E
-0.28x
P/B
0.24x
P/S
34.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$848.00k
Earnings
-$48.19M
Gross Margin
100%
Operating Margin
-5,682.19%
Profit Margin
-5,682.2%
Debt to Equity
0.07
Operating Cash Flow
-$44M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

RLYB Overview

Rallybio Corporation is a clinical-stage biotechnology company offering programs for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company is also focused on developing therapies that address diseases of complement dysregulation, including Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, and ophthalmic disorders. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, CT.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine RLYB's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
RLYB
Ranked
Unranked of 461

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important RLYB news, forecast changes, insider trades & much more!

RLYB News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RLYB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RLYB ($0.31) is undervalued by 48.58% relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RLYB ($0.31) is significantly undervalued by 48.58% relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RLYB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RLYB due diligence checks available for Premium users.

Valuation

RLYB fair value

Fair Value of RLYB stock based on Discounted Cash Flow (DCF)

Price
$0.31
Fair Value
$0.60
Undervalued by
47.91%
RLYB ($0.31) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RLYB ($0.31) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RLYB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RLYB price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.28x
Industry
-116.75x
Market
30.29x

RLYB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.24x
Industry
4.49x
RLYB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RLYB's financial health

Profit margin

Revenue
$212.0k
Net Income
-$9.4M
Profit Margin
-4,452.4%
RLYB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RLYB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$58.0M
Liabilities
$3.9M
Debt to equity
0.07
RLYB's short-term assets ($57.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLYB's short-term assets ($57.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLYB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.2M
Investing
$11.1M
Financing
$0.0
RLYB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RLYB vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
RLYB$12.73M-6.13%-0.28x0.24x
IBIOD$12.74M-14.33%-2.49x1.12x
ABP$12.70M-4.13%-0.30x-0.69x
NEUP$12.78M+2.72%N/A0.76x
ACXP$12.91M-23.61%-0.79x5.59x

Rallybio Stock FAQ

What is Rallybio's quote symbol?

(NASDAQ: RLYB) Rallybio trades on the NASDAQ under the ticker symbol RLYB. Rallybio stock quotes can also be displayed as NASDAQ: RLYB.

If you're new to stock investing, here's how to buy Rallybio stock.

What is the 52 week high and low for Rallybio (NASDAQ: RLYB)?

(NASDAQ: RLYB) Rallybio's 52-week high was $1.60, and its 52-week low was $0.22. It is currently -80.88% from its 52-week high and 39.09% from its 52-week low.

How much is Rallybio stock worth today?

(NASDAQ: RLYB) Rallybio currently has 41,613,964 outstanding shares. With Rallybio stock trading at $0.31 per share, the total value of Rallybio stock (market capitalization) is $12.73M.

Rallybio stock was originally listed at a price of $14.10 in Jul 29, 2021. If you had invested in Rallybio stock at $14.10, your return over the last 3 years would have been -97.83%, for an annualized return of -72.11% (not including any dividends or dividend reinvestments).

How much is Rallybio's stock price per share?

(NASDAQ: RLYB) Rallybio stock price per share is $0.31 today (as of Jun 20, 2025).

What is Rallybio's Market Cap?

(NASDAQ: RLYB) Rallybio's market cap is $12.73M, as of Jun 23, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Rallybio's market cap is calculated by multiplying RLYB's current stock price of $0.31 by RLYB's total outstanding shares of 41,613,964.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.